In the fourth quarter, Eyebright Medical Technology (Beijing) Co., Ltd. saw a more than 30% decline in net profit compared to the previous quarter, due to a decrease in the prices of products under centralized purchasing and changes in revenue structure p

① The company's series of artificial lenses such as 'Punoming' and 'Punotong' corneal reshaping lenses have maintained year-on-year growth in revenue, while vision care products continue to grow rapidly, accounting for about 30% of revenue. ② The company's contact lens Business has turned losses into profits, and it is increasing related production capacity. After the completion of the fundraising investment project, an annual production capacity of 0.252 billion contact lenses and 500 million pairs of molds will be formed.

cls.cnFeb 6 08:24 ET

The price of natural bezoar has risen under pressure, and Zhangzhou Pientzehuang Pharmaceutical's profit growth rate has returned to that of ten years ago.

The "Medicine Mace" Zhangzhou Pientzehuang Pharmaceutical (600436.SH) is entering a "slowdown" period. On January 24th, Zhangzhou Pientzehuang Pharmaceutical released the 2024 performance brief...

wallstreetcnJan 24 01:56 ET

An new low in eighteen years! Tonghua Dongbao Pharmaceutical expects last year's net income to decline by more than 90% year-on-year, and Q4 performance may not meet expectations | Interpretations

① Affected by the decline in sales revenue due to product price reductions, as well as the termination of research and development projects, Tonghua Dongbao Pharmaceutical expects that its net income attributable to the parent for 2024 will decrease by more than 90% year-on-year. ② Compared to Q4, net income saw a decline quarter-on-quarter, and may not have met the company's previous expectations.

cls.cnJan 20 08:40 ET

Sales growth of core varieties: REMEGEN's revenue in 2024 is expected to increase by more than 50% year-on-year, but it has not yet achieved profitability.

① The company has increased its R&D investment, while sales revenue of Tai Tasi Pu and Vidi Situt Monoclonal Antibody has grown rapidly, with the product gross margin continuing to rise and the sales expense ratio significantly decreasing. Therefore, it is expected that the company will report a net loss in 2024, showing a trend of reduced losses; ② The company's Phase III clinical trial for IgAN of Tai Tasi Pu in China has concluded, and data readout is expected in the first half of 2025.

cls.cnJan 16 08:15 ET

The sales growth of the Paigebin product drives performance increase, with Xiamen Amoytop Biotech achieving a new high in net profit in Q4.

① With the continuous upgrade of hepatitis B chronic prevention and treatment guidelines and the ongoing accumulation of clinical cure scientific evidence, cognitive awareness will be promoted, and the number of patients accepting treatment will show an upward trend; ② Interferon has common side effects such as flu-like symptoms, and relatively, patients have a greater workload in treatment and management, which may affect the treatment choices between doctors and patients.

cls.cnJan 15 09:53 ET

The growth of the diagnosis Sector does not hide the performance decline of Beijing Wantai Biological Pharmacy Enterprise; the Net income in 2024 may hit a new low since its listing. | Interpretations

① Beijing Wantai Biological Pharmacy Enterprise issued a performance reduction announcement, expecting that the net income attributable to the parent company in 2024 will decrease by more than 90% year-on-year; ② The main reason is the significant decline in income and profits from the vaccine Sector, leading to a net loss; ③ In Q4, the company incurred losses again, but the loss amount narrowed compared to the same period in 2023.

cls.cnJan 15 06:41 ET